Steve Scala
Stock Analyst at TD Cowen
(2.77)
# 1,866
Out of 4,876 analysts
31
Total ratings
69.23%
Success rate
12.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Buy | $195 → $225 | $182.31 | +23.42% | 12 | Oct 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $59 | $46.35 | +27.29% | 3 | Oct 7, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $90 → $95 | $69.85 | +36.01% | 1 | Aug 12, 2024 | |
| MRK Merck & Co. | Upgrades: Outperform | $125 → $135 | $79.10 | +70.67% | 1 | Jan 4, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $24.19 | +32.29% | 1 | Jan 4, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $430 → $500 | $775.45 | -35.52% | 8 | May 23, 2023 | |
| NVS Novartis AG | Downgrades: Market Perform | $110 → $105 | $120.01 | -12.51% | 4 | Feb 1, 2021 | |
| RPRX Royalty Pharma | Initiates: Outperform | $55 | $35.87 | +53.33% | 1 | Jul 13, 2020 |
AbbVie
Oct 7, 2024
Maintains: Buy
Price Target: $195 → $225
Current: $182.31
Upside: +23.42%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Hold
Price Target: $53 → $59
Current: $46.35
Upside: +27.29%
AstraZeneca
Aug 12, 2024
Maintains: Buy
Price Target: $90 → $95
Current: $69.85
Upside: +36.01%
Merck & Co.
Jan 4, 2024
Upgrades: Outperform
Price Target: $125 → $135
Current: $79.10
Upside: +70.67%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $24.19
Upside: +32.29%
Eli Lilly and Company
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $775.45
Upside: -35.52%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: $110 → $105
Current: $120.01
Upside: -12.51%
Royalty Pharma
Jul 13, 2020
Initiates: Outperform
Price Target: $55
Current: $35.87
Upside: +53.33%